RESUMEN
Based on documentation from the institution known as Fisicatura-mor (1808-28), and mainly on proceedings involving its official 'accreditation' of medical activities, this analysis of popular therapists opens access to categories like bleeders and healers, who were persecuted for their activities down through the nineteenth century. The curing practices employed by these bleeders and curandeiros ranked low on the hierarchy of procedures acceptable by the Fisicatura-mor. Quantitative data analysis demonstrates a link between these practices and disadvantaged social positions. Also analyzed was information that popular therapists and their clientele provided on these practices and on how they are accepted.
Asunto(s)
Venodisección , Terapias Complementarias , Licencia Médica , Venodisección/economía , Venodisección/historia , Venodisección/tendencias , Brasil/etnología , Terapias Complementarias/economía , Terapias Complementarias/historia , Terapias Complementarias/legislación & jurisprudencia , Terapias Complementarias/tendencias , Historia del Siglo XIX , Licencia Médica/historia , Licencia Médica/tendenciasRESUMEN
Se revisan las indicaciones de la venodisección en los pacientes pediátricos, la topografía del sitio a escoger según la edad del paciente, las técnicas quirúrgicas, las complicaciones esperadas, así como las medidas que deben tomarse en cada caso
Asunto(s)
Humanos , Recién Nacido , Lactante , Preescolar , Niño , Venodisección/instrumentación , Venodisección/métodos , Venodisección/normas , Venodisección/tendencias , VenodisecciónRESUMEN
The PVSG was organized in 1967 to establish effective diagnostic criteria for polycythemia vera, to study the natural history of the disease and to define the optimal treatment. Although polycythemia vera and the other myeloproliferative diseases are relatively uncommon, the PVSG was able to accumulate well over 1,000 patients with these various disorders and to study them according to a total of 15 different protocols. PVSG-01, a long-term randomized controlled study of phlebotomy alone compared with the myelosuppressive agents, 32P or chlorambucil supplemented by phlebotomy, continues to receive follow-up data on 93% of surviving patients 18 years after initiation of the study. During its lifetime, PVSG has developed a widely accepted and highly effective set of criteria for the specific diagnosis of polycythemia vera as well as useful criteria for the diagnosis of essential thrombocythemia. It has gathered an enormous volume of data on the natural history of the myeloproliferative diseases and in particular on the nature of the prevalent complications, such as thrombotic events and hematologic and nonhematologic malignancies. With respect to the final question, the optimal treatment for polycythemia vera, it is apparent that the expectation of a single optimal therapy that would apply to all patients at all ages and stages of the disease was naive. Nevertheless considerable progress has been made. Moreover, the group has defined more precisely than ever before the nature of the complications of the disease and the association of the risks of specific complications with specific forms of therapy. It thus has made it possible to pose the next series of therapeutic questions that must be addressed in this disorder with a greater degree of sophistication than was previously possible.
Asunto(s)
Policitemia Vera/terapia , Enfermedad Aguda , Factores de Edad , Venodisección/tendencias , Clorambucilo/efectos adversos , Clorambucilo/uso terapéutico , Terapia Combinada , Reacciones Falso Positivas , Estudios de Seguimiento , Neoplasias Gastrointestinales/complicaciones , Gota/complicaciones , Gota/tratamiento farmacológico , Hematócrito , Humanos , Hidroxiurea/efectos adversos , Hidroxiurea/uso terapéutico , Leucemia/inducido químicamente , Radioisótopos de Fósforo/efectos adversos , Radioisótopos de Fósforo/uso terapéutico , Agregación Plaquetaria/efectos de los fármacos , Recuento de Plaquetas , Policitemia Vera/complicaciones , Policitemia Vera/diagnóstico , Policitemia Vera/tratamiento farmacológico , Policitemia Vera/mortalidad , Policitemia Vera/radioterapia , Estudios Prospectivos , Prurito/complicaciones , Prurito/tratamiento farmacológico , Neoplasias Cutáneas/complicaciones , Trombosis/etiologíaRESUMEN
The PVSG study is unique in that it is prospective and composed of 432 patients randomized to three treatment arms. This study also provides the opportunity for serial studies of numerous sequential biopsies. Large numbers of cases with sequential biopsies covering the entire long course are essential to appreciate the full spectrum of tissue changes in this disease. The PVSG was initiated in 1967 and in mid-1985 approximately one third of the patients are alive and on protocol. For these reasons, the results must still be considered preliminary. Pretreatment biopsies from patients randomized in the PVSG have been analyzed for total cellularity, megakaryocyte concentration, and reticulin content. Considerable variation in these elements was found in these biopsies. Sequential posttreatment biopsies from these patients have also been studied and correlated with the clinical course of the disease. None of the morphologic parameters analyzed was shown to be of prognostic significance. Early in the course of PV the marrow reticulin content is almost always normal. The length of the developmental stage is unknown and the precise timing of the clinical onset may be difficult. Therefore, the 11% of patients that showed a significant increase in reticulin on initial evaluation may have had PV longer than was indicated clinically. If large numbers of sequential biopsies are studied, an increase in reticulin content can frequently be demonstrated during the active phase of the disease and before the onset of the spent phase. Currently 39 patients (9%) have developed the spent phase, or PPMM. PPMM occurred in about the same incidence in the patients treated with myelosuppressive therapy as by phlebotomy alone, the spent phase occurring in 16 patients treated by phlebotomy alone, 11 with chlorambucil, and 12 with 32P. The course of the reticulin fibrosis is slowly progressive. There is some evidence for regression in a few patients in the erythrocytotic phase, but sampling variation cannot be completely ruled out. At this time in the study, AL has developed in 37 patients (8.6%). The incidence of AL is quite low in the phlebotomy group (three cases). Presumably this represents the natural incidence in PV unmodified by therapeutic agents. The frequency is approximately equal and quite high in the chlorambucil and 32P groups. There are 19 cases in the chlorambucil-treated group and 15 in the 32P-treated group. The leukemias that developed in the PV patients occurred either de novo or following PPMM.(ABSTRACT TRUNCATED AT 400 WORDS)